BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 34318356)

  • 21. Bispecific antibodies in acute lymphoblastic leukemia therapy.
    Chitadze G; Laqua A; Lettau M; Baldus CD; Brüggemann M
    Expert Rev Hematol; 2020 Nov; 13(11):1211-1233. PubMed ID: 33000968
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action.
    Wudhikarn K; Wills B; Lesokhin AM
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101143. PubMed ID: 32139009
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies.
    Tian Z; Liu M; Zhang Y; Wang X
    J Hematol Oncol; 2021 May; 14(1):75. PubMed ID: 33941237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody-Based Treatment Approaches in Multiple Myeloma.
    Hosoya H; Sidana S
    Curr Hematol Malig Rep; 2021 Apr; 16(2):183-191. PubMed ID: 33730360
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new decade: novel immunotherapies on the horizon for relapsed/refractory multiple myeloma.
    Braunstein M; Weltz J; Davies F
    Expert Rev Hematol; 2021 Apr; 14(4):377-389. PubMed ID: 33769179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myeloma: next generation immunotherapy.
    Cohen AD
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):266-272. PubMed ID: 31808859
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma.
    D'Souza A; Shah N; Rodriguez C; Voorhees PM; Weisel K; Bueno OF; Pothacamury RK; Freise KJ; Yue S; Ross JA; Polepally AR; Talati C; Lee S; Jin Z; Buelow B; Vij R; Kumar S
    J Clin Oncol; 2022 Nov; 40(31):3576-3586. PubMed ID: 36029527
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 1, monoclonal antibodies, antibody-drug conjugates and bispecific T-cell engagers.
    Paci A; Desnoyer A; Delahousse J; Blondel L; Maritaz C; Chaput N; Mir O; Broutin S
    Eur J Cancer; 2020 Mar; 128():107-118. PubMed ID: 32037061
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma.
    Stewart AK; Krishnan AY; Singhal S; Boccia RV; Patel MR; Niesvizky R; Chanan-Khan AA; Ailawadhi S; Brumm J; Mundt KE; Hong K; McBride J; Shon-Nguyen Q; Xiao Y; Ramakrishnan V; Polson AG; Samineni D; Leipold D; Humke EW; McClellan JS; Berdeja JG
    Blood Cancer J; 2019 Feb; 9(2):17. PubMed ID: 30718503
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.
    Chari A; Minnema MC; Berdeja JG; Oriol A; van de Donk NWCJ; Rodríguez-Otero P; Askari E; Mateos MV; Costa LJ; Caers J; Verona R; Girgis S; Yang S; Goldsmith RB; Yao X; Pillarisetti K; Hilder BW; Russell J; Goldberg JD; Krishnan A
    N Engl J Med; 2022 Dec; 387(24):2232-2244. PubMed ID: 36507686
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia.
    Buie LW; Pecoraro JJ; Horvat TZ; Daley RJ
    Ann Pharmacother; 2015 Sep; 49(9):1057-67. PubMed ID: 26041811
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia.
    Ribera JM
    Expert Rev Hematol; 2017 Dec; 10(12):1057-1067. PubMed ID: 29082835
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma.
    Granger K; Gaffney KJ; Davis JA
    J Oncol Pharm Pract; 2023 Apr; 29(3):722-726. PubMed ID: 36775940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bispecific T-cell engagers for treatment of multiple myeloma.
    Ravi G; Costa LJ
    Am J Hematol; 2023 Mar; 98 Suppl 2():S13-S21. PubMed ID: 35702871
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.
    Rodriguez-Otero P; van de Donk NWCJ; Pillarisetti K; Cornax I; Vishwamitra D; Gray K; Hilder B; Tolbert J; Renaud T; Masterson T; Heuck C; Kane C; Verona R; Moreau P; Bahlis N; Chari A
    Blood Cancer J; 2024 Feb; 14(1):24. PubMed ID: 38307865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies.
    Sanchez L; Dardac A; Madduri D; Richard S; Richter J
    Ther Adv Hematol; 2021; 12():2040620721989585. PubMed ID: 33796236
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel approaches to the treatment of multiple myeloma.
    Maples KT; Scott SA; Lonial S
    Clin Adv Hematol Oncol; 2023 May; 21(5):247-256. PubMed ID: 37145495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bispecific Antibodies for the Treatment of Multiple Myeloma.
    Goldsmith SR; Streeter S; Covut F
    Curr Hematol Malig Rep; 2022 Dec; 17(6):286-297. PubMed ID: 36029366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies.
    Tapia-Galisteo A; Álvarez-Vallina L; Sanz L
    J Hematol Oncol; 2023 Jul; 16(1):83. PubMed ID: 37501154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting.
    Raje NS; Cohen AD; Patel KK; van de Donk NWCJ; Richter J; San-Miguel J
    Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):350-357. PubMed ID: 38627181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.